Wockhardt Expands UK Vaccines Unit With Serum Institute Deal
Serum Life Sciences Collaboration Will Include New Facility In Wrexham
India’s Wockhardt has announced a fresh collaboration with the Serum Institute of India that will see the firm create a new sterile fill-and-finish facility in the UK, as part of plans to deliver an additional 150 million vaccine doses.
You may also be interested in...
Under deal amendment, Innovent gets Asia rights to Cyramza, Retevmo and pirtobrutinib.
Indian pharmaceutical firm Wockhardt is set to export up to 100 million doses of the Russian COVID-19 vaccine Sputnik V, through a technology transfer agreement with the Gamaleya National Research Institute of Epidemiology and Microbiology.
Wockhardt’s UK segment continues to grow as the company records a 66% increase for the second quarter ending 30 September 2021. The company’s India market and Irish market performed well, while its emerging markets and US market failed to deliver.